iteos news - Search News

GSK, iTeos

Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of lung cancer.

YAHOO!Finance · 6d

TIGIT drug from iTeos shrinks lung tumors in trial

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Bloomberg L.P. · 7d

GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of setbacks.

Seeking Alpha on MSN · 6d

GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial

Teos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy dostarlimab,

MarketWatch · 5d

ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study

Shares in iTeos Therapeutics rose after the company reported positive data from a mid-stage study exploring the combination of belrestotug and dostarlimab in the first-line treatment of lung cancer. Shares were up 22% in premarket trading at $20.40. The stock is up more than 52% this year.

FierceBiotech7d

UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

4don MSN

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Monday. Shares of iTeos ...

GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

6d

Buy Rating Affirmed for iTeos Therapeutics Amid Promising Lung-201 Study Outcomes

Eva Fortea Verdejo, an analyst from Wells Fargo, maintained the Buy rating on iTeos Therapeutics (ITOS – Research Report). The associated ...

6d

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

ESMO: GSK, iTeos bring some optimism back to TIGIT

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

ENDPOINTS NEWS7d

GSK, iTeos rejuvenate struggling TIGIT space with positive Phase 2 Jemperli combo data in lung cancer

GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, ...

Investor's Business Daily on MSN4d

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results